Literature DB >> 14760333

Relationship between heart failure treatment and development of worsening renal function among hospitalized patients.

Javed Butler1, Daniel E Forman, William T Abraham, Stephen S Gottlieb, Evan Loh, Barry M Massie, Christopher M O'Connor, Michael W Rich, Lynne Warner Stevenson, Yongfei Wang, James B Young, Harlan M Krumholz.   

Abstract

BACKGROUND: Among patients who are hospitalized with heart failure (HF), worsening renal function (WRF) is associated with worse outcomes. Whether treatment for HF contributes to WRF is unknown. In this study, we sought to assess whether acute treatment for patients who were hospitalized with HF contributes to WRF.
METHODS: Data were collected in a nested case-control study on 382 subjects who were hospitalized with HF (191 patients with WRF, defined as a rise in serum creatinine level >26.5 micromol/L [0.3 mg/dL], and 191 control subjects). The association of medications, fluid intake/output, and weight with WRF was assessed.
RESULTS: Calcium channel blocker (CCB) use and loop diuretic doses were higher in patients on the day before WRF (25% vs 10% for CCB; 199 +/- 195 mg vs 143 +/- 119 mg for loop diuretics; both P <.05). There were no significant differences in the fluid intake/output or weight changes in the 2 groups. Angiotensin-converting enzyme (ACE) inhibitor use was not associated with WRF. Other predictors of WRF included elevated creatinine level at admission, uncontrolled hypertension, and history of HF or diabetes mellitus. Higher hematocrit levels were associated with a lower risk. Vasodilator use was higher among patients on the day before WRF (46% vs 35%, P <.05), but was not an independent predictor in the multivariable analysis.
CONCLUSIONS: Several medical strategies, including the use of CCBs and a higher dose of loop diuretics, but not ACE inhibitors, were associated with a higher risk of WRF. Although assessment of inhospital diuresis was limited, WRF could not be explained by greater fluid loss in these patients. Determining whether these interventions are responsible for WRF or are markers of higher risk requires further investigation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14760333     DOI: 10.1016/j.ahj.2003.08.012

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  106 in total

Review 1.  Retroelements and formation of chimeric retrogenes.

Authors:  A A Buzdin
Journal:  Cell Mol Life Sci       Date:  2004-08       Impact factor: 9.261

2.  What have we learned about loop diuretics in acute decompensated heart failure? The DOSE trial.

Authors:  Dmitry Shchekochikhin; JoAnn Lindenfeld
Journal:  Curr Cardiol Rep       Date:  2012-06       Impact factor: 2.931

3.  Worsening renal function defined as an absolute increase in serum creatinine is a biased metric for the study of cardio-renal interactions.

Authors:  Jeffrey M Testani; Brian D McCauley; Jennifer Chen; Michael Shumski; Richard P Shannon
Journal:  Cardiology       Date:  2010-08-03       Impact factor: 1.869

4.  Management of the cardiorenal syndrome in acute heart failure.

Authors:  Valentina Lazzarini; G Michael Felker
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-08

5.  Ultrafiltration in patients with decompensated heart failure and diuretic resistance: an Asian centre's experience.

Authors:  Loon Yee Louis Teo; Choon Pin Lim; Chia Lee Neo; Lee Wah Teo; Swee Ling Elaine Ng; Laura Lihua Chan; Manish Kaushik; Kheng Leng David Sim
Journal:  Singapore Med J       Date:  2016-01-15       Impact factor: 1.858

Review 6.  Hypertonic saline plus i.v. furosemide improve renal safety profile and clinical outcomes in acute decompensated heart failure: A meta-analysis of the literature.

Authors:  R De Vecchis; C Esposito; C Ariano; S Cantatrione
Journal:  Herz       Date:  2014-03-30       Impact factor: 1.443

Review 7.  Ultrafiltration in decompensated heart failure.

Authors:  Brian E Jaski; David Miller
Journal:  Curr Heart Fail Rep       Date:  2005-09

8.  The role of ultrafiltration in the management of heart failure.

Authors:  Maria Rosa Costanzo
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-08

Review 9.  Benefit-risk assessment of nesiritide in the treatment of acute decompensated heart failure.

Authors:  Clyde W Yancy
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

10.  Optimal use of diuretics in patients with heart failure.

Authors:  Jigar Patel; Michael Smith; J Thomas Heywood
Journal:  Curr Treat Options Cardiovasc Med       Date:  2007-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.